interim analysis - Robuta Search

https://scholarlyexchange.childrensmercy.org/posters/255/ "Development and Interim Analysis of a Cystic Fibrosis-Specific Antibio" by Claire Elson, Ellen... Antimicrobial therapy is essential to treat cystic fibrosis (CF) lung infections. Empiric antimicrobial selection is generally based on previous culture... interim analysis cystic fibrosis development specific claire https://vascularspecialistonline.com/interim-analysis-provides-early-window-into-real-world-alto-stent-graft-outcomes/ Interim analysis provides early window into real-world Alto stent graft outcomes - Vascular... Sep 1, 2026 - In a podium-first presentation on the final day of the 2024 Charing Cross (CX) International Symposium (23–25 April, London, UK), Sean Lyden (Cleveland Clinic,... interim analysis real world stent graft provides early https://www.tevapharm.com/news-and-media/latest-news/tevas-3rd-interim-analysis-of-pearl-real-world-study-on-ajovy-fremanezumab-reveals-sustained-long-ter/ Teva’s 3rd interim analysis of PEARL real-world study on AJOVY® (fremanezumab) reveals sustained... interim analysis real world pearl study fremanezumab https://journals.plos.org/plosmedicine/article/peerReview?id=10.1371/journal.pmed.1003222 Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a... In an interim analysis of a multi-center open-label study, Edward Smith and colleagues investigate motor outcomes and adverse events in patients with Duchenne... duchenne muscular dystrophy interim analysis efficacy safety vamorolone https://discovery.dundee.ac.uk/en/publications/interim-analysis-of-medici-mammographic-predictors-of-cancer-recu/ Interim Analysis of MEDICI: Mammographic Predictors of Cancer Recurrence after Breast Conservation... interim analysis cancer recurrence medici mammographic predictors https://www.astrazeneca-us.com/media/press-releases/2019/imfinzi-durvalumab-improves-overall-survival-at-interim-analysis-in-the-phase-iii-caspian-trial-in-1st-line-extensive-stage-small-cell-lung-cancer-06272019.html IMFINZI® (durvalumab) improves overall survival at interim analysis in the Phase III CASPIAN trial... overall survival interim analysis the phase durvalumab improves https://www.healthcarewirehongkong.com/article/889317282-pharmazz-presents-positive-phase-iv-interim-analysis-of-sovateltide-for-acute-ischemic-stroke-at-the-international-stroke-conference-2026 Pharmazz Presents Positive Phase IV Interim Analysis of Sovateltide for Acute Ischemic Stroke at... acute ischemic stroke phase iv interim analysis presents positive https://labn.org/los-angeles-biotech-news/2026/06/01/turn-therapeutics-reports-interim-analysis-findings-and-adaptive-optimization-strategy-from-phase-2-gx-03-trial-in-moderate-to-severe-atopic-dermatitis/ Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2... Jun 1, 2026 - WESTLAKE VILLAGE, Calif.–(BUSINESS WIRE)–Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies... interim analysis adaptive optimization turn therapeutics reports https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/azd1222-us-phase-iii-trial-met-primary-efficacy--endpoint-in-pre.html AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis phase iii trial primary efficacy endpoint interim analysis met preventing https://medicaex.com/prnewswire/asieris-announces-positive-interim-analysis-results-in-phase-ii-clinical-trial-of-oral-apl-1202-in-combination-with-tislelizumab-a-pd-1-inhibitor-as-neoadjuvant-therapy-for-muscle-invasive-bladder-c/ Asieris Announces Positive Interim Analysis Results in Phase II Clinical Trial of Oral APL-1202 in... Sep 18, 2023 - SHANGHAI, Sept. 13, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and... interim analysis phase ii clinical trial announces positive https://www.techtrendsfrenchpolynesia.com/article/889317282-pharmazz-presents-positive-phase-iv-interim-analysis-of-sovateltide-for-acute-ischemic-stroke-at-the-international-stroke-conference-2026 Pharmazz Presents Positive Phase IV Interim Analysis of Sovateltide for Acute Ischemic Stroke at... acute ischemic stroke phase iv interim analysis presents positive https://zenopa.com/news/maat-pharma-announces-positive-safety-interim-analysis-from-dsmb-for-phase-2b-trial-evaluating-maat033-for-patients-receiving-allo-hsct MaaT Pharma Announces Positive Safety Interim Analysis from DSMB for Phase 2b Trial Evaluating... Feb 19, 2026 - Following a milestone unblinded interim safety review, the independent Data Safety Monitoring Board (DSMB) has recommended that the study proceed without... maat pharma interim analysis announces positive safety